Choose endotoxin testing around the sample you actually have. Creative BioMart provides endotoxin testing services for blood-based samples, other body fluids and E. coli-related research materials. Explore the matrix-specific services below and discuss your sample source, preparation history and analytical objective with our team.
The sample matrix is everything surrounding the endotoxin being measured. Proteins, lipids, salts, cells, collection additives and processing reagents can affect assay response or the amount of endotoxin recovered. A procedure suitable for a simple aqueous preparation may therefore require additional evaluation before use with a biological fluid or bacterial process sample.
Begin with the material submitted for analysis, rather than its source alone. Whole blood, separated plasma and serum are different matrices. Likewise, an E. coli culture supernatant, cell lysate and purified recombinant product represent different testing situations. Clear sample identification helps connect the analytical result to the intended research or process question.
Endotoxin Testing in Blood, Plasma and Serum
Use the blood service for an initial discussion or choose the dedicated plasma or serum page when the submitted fraction is already defined.
Discuss testing for blood-based research samples, including the fraction to be analyzed and any separation steps. Collection tubes, anticoagulants, processing intervals and visible hemolysis are useful details when reviewing preparation and potential interference.
Explore the specific blood fraction: Endotoxin Testing in Plasma — identify the anticoagulant and separation history; plasma components and collection additives can influence recovery. Endotoxin Testing in Serum — describe clotting, separation and storage conditions; a serum result should be interpreted using a procedure evaluated for that matrix.
Start with this broader service if your fluid type is not listed or the project covers several matrices. Specify whether the sample is native fluid, a cell-free fraction, a lavage specimen or a diluted preparation. These distinctions help define what the reported concentration represents.
Plan testing around available volume, sample handling and any blood contamination. Small sample quantities make it useful to agree on the allocation for preparation, controls and repeat measurements before testing.
Provide the lavage solution, collection procedure and any centrifugation or filtration details. Distinguish the collected specimen from the original airway fluid when defining reporting units and comparisons between samples.
Describe specimen appearance, cell content and any previous clarification. Protein-rich, cloudy or blood-contaminated preparations may present different analytical challenges, so preparation should be linked to the fraction being evaluated.
Discuss research testing for peritoneal fluid or ascitic samples. State whether the material is native fluid or includes lavage solution, and identify preservatives or other additions that may affect the testing conditions.
Plan testing with information about collection, preservatives, pH and visible sediment. For comparisons across samples or time points, define the concentration basis and any proposed normalization before analysis.
Discuss endotoxin measurements in E. coli-related research and process samples. Identify whether you are submitting culture medium, supernatant, a cell suspension, lysate or a downstream fraction, together with any extraction or dilution already performed.
For a purified recombinant protein, the final formulation may be the more useful starting point. See Endotoxin Testing in Recombinant Proteins for that product-focused route. Endotoxin measurement is separate from bacterial identification, viable counting and testing for protein exotoxins.
Research and analytical scope. These services support sample characterization and defined analytical projects. Results are not offered here as a stand-alone diagnosis of infection, sepsis or another disease, or as a basis for treatment decisions.
Compare Matrix-Specific Planning Considerations
Use this guide to prepare an enquiry. The actual sample, testing objective and available material determine the work needed.
On smaller screens, scroll horizontally to view all comparison columns.
Sample matrix
Details to provide
Planning focus
Result interpretation
Blood, plasma and serum
Fraction, collection tube, anticoagulant and processing
Evaluate matrix effects and preparation for the submitted fraction
Avoid treating different fractions as interchangeable
Cerebrospinal fluid
Volume, handling and visible blood contamination
Allocate limited material for the agreed tests and controls
Relate the result to the actual tested preparation
Bronchoalveolar lavage fluid
Lavage solution and collection or processing details
Account for collection-related dilution and added materials
Report on the collected sample basis unless another basis is justified
Pleural and peritoneal fluids
Fluid source, appearance, cell fraction and additions
Define the fraction and preparation to be assessed
Consider preparation differences in cross-sample comparisons
Urine
Collection, preservatives, pH and sediment
Review compatibility and the proposed reporting basis
Define any normalization separately from the assay measurement
E. coli-related materials
Process stage, medium, lysis reagents and dilution
Match preparation and measurement range to the material
Distinguish endotoxin results from bacterial counts or identity
Build a Testing Strategy for the Matrix
Method selection follows the analytical question and sample properties. Gel-clot testing can address a defined threshold, while suitable chromogenic, turbidimetric or recombinant Factor C approaches may support quantitative measurements. No readout is automatically suitable for every biological matrix.
Your project situation
A useful next step
A new biological matrix
Define preparation, controls and recovery assessment before applying routine conditions.
A colored, cloudy or concentrated sample
Review both optical effects and interference with the assay reaction. Assess preparation or dilution without losing the required analytical range.
Low recovery or inconsistent results
Review collection additives, handling, preparation and assay controls before interpreting the difference as a change in endotoxin.
Samples from several sources or time points
Agree on collection, processing and reporting conventions so that differences in the matrix do not obscure the intended comparison.
Send the matrix and species, sample count, available volume, collection additives, preparation history and intended use. Include expected levels or previous results, requested units and any target threshold.
Identify the specimen: state whether it is native fluid, a separated fraction, a diluted sample or a processed bacterial material.
Document handling: provide collection-to-storage timing, storage temperature and freeze-thaw history. Discuss shipment and sample acceptance before sending material.
Define the comparison: identify study groups or process stages and explain the question the results should address.
Agree on deliverables: confirm the method, preparation, controls, reporting basis and schedule with our team.
For a product specification, provide the applicable limit and intended use so that dilution constraints can be reviewed. Biological research fluids do not automatically inherit the acceptance limits used for injectable products.
Frequently Asked Questions
Should I choose blood, plasma or serum testing?
Choose the page matching the fraction you plan to submit. If that has not been decided, start with blood testing and describe the research objective. Confirm collection and separation requirements before preparing a new sample set.
Do anticoagulants matter for plasma testing?
Yes. Collection additives can affect the assay environment and endotoxin recovery. Provide the anticoagulant identity and tube details; do not assume conditions established for one collection system transfer directly to another.
Can one preparation procedure be used for every body fluid?
Not automatically. Fluid composition, added materials and the fraction of interest differ. A preparation step also changes what is being tested, so its purpose and suitability should be evaluated for the submitted matrix.
Can I compare lavage fluid results directly with native fluid concentrations?
Not without accounting for collection and the reporting basis. A result per milliliter of collected lavage fluid does not directly establish the concentration in the original undiluted fluid. Record the collection procedure and discuss any proposed correction.
Does an acceptable spike recovery prove that all native endotoxin has been recovered?
No. It supports assessment of interference under the tested conditions. Recovery of an added standard does not by itself establish complete recovery of endotoxin already associated with biological components or altered during prior handling.
Does a below-range result mean the sample contains no endotoxin?
No. Interpret the result against the reporting limit for the prepared sample, including dilution. A below-range result does not establish absolute absence, and an invalid test should not be reported as a negative result.
Does testing an E. coli sample measure live bacteria?
No. Endotoxin testing measures an endotoxin-related assay response under defined conditions. It does not identify the organism or measure viable cells, and there is no universal conversion from endotoxin units to a bacterial count.
How much sample is needed, and can archived specimens be tested?
Requirements depend on preparation, dilution, controls and the number of measurements. Provide the available volume and storage history, including freeze-thaw cycles. Feasibility and any limits on interpretation can then be discussed before committing scarce material.
Discuss Your Sample Matrix and Testing Objective
Share your sample type, handling history and the question you need to answer. Our team will review the information and discuss the testing scope, sample requirements and quotation.
United States Pharmacopeia. General Chapter <85>: Bacterial Endotoxins Test.
United States Pharmacopeia. General Chapter <86>: Bacterial Endotoxins Test Using Recombinant Reagents.
U.S. Food and Drug Administration. Pyrogen and Endotoxins Testing: Questions and Answers. Edition 2. March 2026.
Harm S, Schildböck C, Strobl K, Hartmann J. An in vitro study on factors affecting endotoxin neutralization in human plasma using the Limulus amebocyte lysate test. Sci Rep. 2021;11(1):4192. doi:10.1038/s41598-021-83487-4
Harm S, Schildböck C, Cont D, Weber V. Heparin enables the reliable detection of endotoxin in human serum samples using the Limulus amebocyte lysate assay. Sci Rep. 2024;14(1):2410. doi:10.1038/s41598-024-52735-8
